Efficacy assessment of FLASH radiotherapy on 3D cancer spheroids cultured in lab-on-chips

Non melanoma skin cancer, comprising basal cell and squamous cell carcinomas, are the most common cancers with over 75000 cases/year in Canada. They are curable with radiotherapy or surgery with recurrence rates less than 10% with either modality. Age is an important risk factor (the median age is > 65 years of age); many patients are frail and elderly. FLASH is a new modality potentially permitting radiation therapy in just a single session. However, the optimal dosing has not been established. Testing with standard 2D cell lines is not representative of the 3D architecture of cancer. We wish to combine 3D culture (spheroids) using the MISO Chip devices with FLASH to determine optimal dosing and improve biology relevance of our in vitro results. Prompting this new technology will benefit the Canadian manufacturer of MISO Chip in demonstrating its applicability in the field of FLASH radiation and benefit Canadian cancer patients, by paving the way for a simpler and better treatment option.

Faculty Supervisor:

David Roberge;Philip Wong

Student:

Partner:

MISO Chip Inc.

Discipline:

Life Sciences

Sector:

Manufacturing; Professional, scientific and technical services

University:

Université de Montréal

Program: